Navigation Links
Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD
Date:2/11/2010

SINGAPORE, Feb. 11 /PRNewswire-Asia/ -- The January issue of "Neuropharmacology", publishes the article entitled "Neuroprotective and Neuroproliferative Activities of NeuroAiD", reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

The French research team was led by Prof. Michel Lazdunski, world-renowned specialist of pharmacology.

The data demonstrates NeuroAiD effects on decreasing cognitive deficits, preventing death of threatened neuronal tissues and improving functional outcomes by repairing and restoring neuronal circuits. This is fully consistent with clinical observations of NeuroAiD efficacy as a post stroke treatment.

NeuroAiD treatment increases survival rate, reduces infarct volume, prevents neuronal death and drastically decreases functional deficits in rodents' stroke models. The data also shows NeuroAiD effectiveness in reducing stroke severity when administrated preventively.

The results show that NeuroAiD triggers the synthesis of Brain Derived Neurotrophic Factor (BDNF), which is known to promote neuroplasticity. Indeed NeuroAiD induces neurogenesis in rodent and human cells, and stimulates the development of new neuronal circuits of information.

Previous trials and clinical reports conducted in Asia have already demonstrated high levels of NeuroAiD safety and efficacy in improving stroke rehabilitation, even when taken several months after stroke onset. NeuroAiD Stroke Treatment is already available in many countries in Asia and in the Middle East for stroke survivors. New clinical assessments will be conducted in France and Europe shortly on stroke recovery.

David Picard, CEO of Moleac, said "We are extremely enthusiastic and proud to see these data published. It is a strong validation of our research of active ingredients in NeuroAiD as well as of our efforts towards continuous optimization of its formula. These results pave the way for new indications of NeuroAiD beyond stroke recovery such as prevention, cognitive impairments and dementia. It is good news for patients who are in need of treatment in this under-served therapeutic area."

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide. http://www.moleac.net

About NeuroAiD

NeuroAiD is a stroke treatment to help stroke patients achieve faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries. http://www.neuroaid.com

    Contact details:

     Kasia Kaminska
     Tel: +65-64789432
     Kasia.kaminska@moleac.net

SOURCE Moleac

RELATED LINKS
http://www.moleac.net
http://www.neuroaid.com

'/>"/>

SOURCE Moleac
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards
2. Moleac Launches NeuroAid10(TM) in the United States
3. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
4. Kinexus Announces the Launch of a New Protein Kinase Microarray
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions
10. Angiotech Pharmaceuticals Announces Conference Call and Webcast
11. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):